Anticholinesterase and Antioxidant Investigations of Crude Extracts, Subsequent Fractions, Saponins and Flavonoids of Atriplex Laciniata L.: Potential Effectiveness in Alzheimer's and Other Neurological Disorders

Overview

Journal Biol Res

Specialty Biology

Date 2015 Apr 19

PMID 25889712

Citations 36

Authors

Zul Kamal

Farhat Ullah

Muhammad Ayaz

Abdul Sadiq

Sajjad Ahmad

Anwar Zeb

Abid Hussain

Muhammad Imran

Affiliations

Soon will be listed here.

Abstract

Background: Atriplex laciniata L. was investigated for phenolic, flavonoid contents, antioxidant, anticholinesterase activities, in an attempt to explore its effectiveness in Alzheimer's and other neurological disorders. Plant crude methanolic extract (Al.MeF), subsequent fractions; n-hexane (Al.HxF), chloroform (Al.CfF), ethyl acetate (Al.EaF), aqueous (Al.WtF), Saponins (Al.SPF) and Flavonoids (Al.FLVF) were investigated for DPPH, ABTS and H2O2 free radical scavenging activities. Further these extracts were subjected to acetylcholinesterase (AChE) & butyrylcholinesterase (BChE) inhibitory activities using Ellman's assay. Phenolic and Flavonoid contents were determined and expressed in mg Gallic acid GAE/g and Rutin RTE/g of samples respectively.

Results: In DPPH free radicals scavenging assay, Al.FLVF, Al.SPF and Al.MeF showed highest activity causing 89.41 ± 0.55, 83.37 ± 0.34 and 83.37 ± 0.34% inhibition of free radicals respectively at 1 mg/mL concentration. IC50 for these fractions were 33, 83 and 82 μg/mL respectively. Similarly, plant extracts showed high ABTS scavenging potential, i.e. Al.FLVF (90.34 ± 0.55), Al.CfF (83.42 ± 0.57), Al.MeF (81.49 ± 0.60) with IC50 of 30, 190 and 70 μg/ml respectively. further, H2O2 percent scavenging was highly appraised in Al.FLVF (91.29 ± 0.53, IC50 75), Al.SPF (85.35 ± 0.61, IC50 70) and Al.EaF (83.48 ± 0.67, IC50 270 μg/mL). All fractions exhibited concentration dependent AChE inhibitory activity as; Al.FLVF, 88.31 ± 0.57 (IC50 70 μg/mL), Al.SPF, 84.36 ± 0.64 (IC50 90 μg/mL), Al.MeF, 78.65 ± 0.70 (IC50 280 μg/mL), Al.EaF, 77.45 ± 0.46 (IC50 270 μg/mL) and Al.WtF 72.44 ± 0.58 (IC50 263 μg/mL) at 1 mg/mL. Likewise the percent BChE inhibitory activity was most obvious in Al.FLVF 85.46 ± 0.62 (IC50 100 μg/mL), Al.CfF 83.49 ± 0.46 (IC50 160 μg/mL), Al.MeF 82.68 ± 0.60 (IC50 220 μg/mL) and Al.SPF 80.37 ± 0.54 (IC50 120 μg/mL).

Conclusions: These results stipulate that A. laciniata is enriched with phenolic and flavonoid contents that possess significant antioxidant and anticholinestrase effects. This provide pharmacological basis for the presence of compounds that may be effective in Alzheimer's and other neurological disorders.

Citing Articles

Evaluation of the Ameliorative Potential of 3,5-(2-hydroxyethyl)-1,3,5-thiadiazinane-2-thione against Scopolamine-Induced Alzheimer's Disease.

Shagufta , Ali G, Khan A, Rasheed A, Deeba F, Ullah R Int J Mol Sci. 2024; 25(16).

PMID: 39201791 PMC: 11354520. DOI: 10.3390/ijms25169104.

Combining Deep Learning and Structural Modeling to Identify Potential Acetylcholinesterase Inhibitors from .

Sutthibutpong T, Posansee K, Liangruksa M, Termsaithong T, Piyayotai S, Phitsuwan P ACS Omega. 2024; 9(14):16311-16321.

PMID: 38617639 PMC: 11007777. DOI: 10.1021/acsomega.3c10459.

Phytochemical investigation and anti-inflammatory potential of Atriplex leucoclada Boiss.

Ahmed H, Mohamed E, Amin E, Moawad A, Abdel-Bakky M, Almahmoud S BMC Complement Med Ther. 2023; 23(1):464.

PMID: 38104070 PMC: 10725009. DOI: 10.1186/s12906-023-04281-5.

Cognition Enhancing Potential of Aqueous Leaf Extract of in Mice.

Kipkemoi D, Ireri A, Ngugi M J Evid Based Integr Med. 2023; 28:2515690X231211661.

PMID: 37960857 PMC: 10644747. DOI: 10.1177/2515690X231211661.

Aromatherapy for the brain: Lavender's healing effect on epilepsy, depression, anxiety, migraine, and Alzheimer's disease: A review article.

Hatami Bavarsad N, Bagheri S, Kourosh-Arami M, Komaki A Heliyon. 2023; 9(8):e18492.

PMID: 37554839 PMC: 10404968. DOI: 10.1016/j.heliyon.2023.e18492.

References

Re R, Pellegrini N, Proteggente A, Pannala A, Yang M . Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med. 1999; 26(9-10):1231-7. DOI: 10.1016/s0891-5849(98)00315-3. View

De Strooper B, Annaert W . Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000; 113 ( Pt 11):1857-70. DOI: 10.1242/jcs.113.11.1857. View

Pietta P . Flavonoids as antioxidants. J Nat Prod. 2000; 63(7):1035-42. DOI: 10.1021/np9904509. View

Perry N, Houghton P, Theobald A, Jenner P, Perry E . In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol. 2000; 52(7):895-902. DOI: 10.1211/0022357001774598. View

Refolo L, Pappolla M, Lafrancois J, Malester B, Schmidt S, Tint G . A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001; 8(5):890-9. DOI: 10.1006/nbdi.2001.0422. View

Lashuel H, Hartley D, Petre B, Walz T, Lansbury Jr P . Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002; 418(6895):291. DOI: 10.1038/418291a. View

Howes M, Perry N, Houghton P . Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res. 2003; 17(1):1-18. DOI: 10.1002/ptr.1280. View

Ichikawa H, Ichiyanagi T, Xu B, Yoshii Y, Nakajima M, Konishi T . Antioxidant Activity of Anthocyanin Extract from Purple Black Rice. J Med Food. 2003; 4(4):211-218. DOI: 10.1089/10966200152744481. View

Howes M, Houghton P . Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav. 2003; 75(3):513-27. DOI: 10.1016/s0091-3057(03)00128-x. View

10.

Tildesley N, Kennedy D, Perry E, Ballard C, Savelev S, Wesnes K . Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav. 2003; 75(3):669-74. DOI: 10.1016/s0091-3057(03)00122-9. View

11.

Shahidi F, Wanasundara P . Phenolic antioxidants. Crit Rev Food Sci Nutr. 1992; 32(1):67-103. DOI: 10.1080/10408399209527581. View

12.

Allain H, Bentue-Ferrer D, Tribut O, Gauthier S, Michel B, Drieu-La Rochelle C . Alzheimer's disease: the pharmacological pathway. Fundam Clin Pharmacol. 2003; 17(4):419-28. DOI: 10.1046/j.1472-8206.2003.00153.x. View

13.

Rinaldi P, Polidori M, Metastasio A, Mariani E, Mattioli P, Cherubini A . Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging. 2003; 24(7):915-9. DOI: 10.1016/s0197-4580(03)00031-9. View

14.

Ellman G, COURTNEY K, ANDRES Jr V, FEATHER-STONE R . A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961; 7:88-95. DOI: 10.1016/0006-2952(61)90145-9. View

15.

Heinrich M, Lee Teoh H . Galanthamine from snowdrop--the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J Ethnopharmacol. 2004; 92(2-3):147-62. DOI: 10.1016/j.jep.2004.02.012. View

16.

Lopes D, Caruso R, Castro N, Costa P, da Silva A, Noel F . Characterization of a new synthetic isoflavonoid with inverse agonist activity at the central benzodiazepine receptor. Eur J Pharmacol. 2004; 495(2-3):87-96. DOI: 10.1016/j.ejphar.2004.05.026. View

17.

Yasar S, Corrada M, Brookmeyer R, Kawas C . Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 2004; 26(2):157-63. DOI: 10.1016/j.neurobiolaging.2004.03.009. View

18.

Szilagyi G, Nagy Z, Balkay L, Boros I, Emri M, Lehel S . Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci. 2005; 229-230:275-84. DOI: 10.1016/j.jns.2004.11.053. View

19.

Anekonda T, Reddy P . Can herbs provide a new generation of drugs for treating Alzheimer's disease?. Brain Res Brain Res Rev. 2005; 50(2):361-76. DOI: 10.1016/j.brainresrev.2005.09.001. View

20.

Reddy P, Beal M . Are mitochondria critical in the pathogenesis of Alzheimer's disease?. Brain Res Brain Res Rev. 2005; 49(3):618-32. DOI: 10.1016/j.brainresrev.2005.03.004. View